Vectalys will attend the ASGCT 20th annual meeting in Washington, DC May 10-13, 2017 and will be presenting a poster on efficient KO of PD1 and CXCR4 into primary T cells using LentiFlash.
The goal is to up-grade its scalable lentiviral bioproduction platform into GMP to provide both integrative lentiviral vectors for T-cell immunotherapies and LentiFlashTM particles for gene-editing...
Vectalys will attend the AACR Annual Meeting in Washington DC, April 1-5, 2017.
Vectalys attended the CRISPR congress Berlin 2016 to present an innovative RNA delivery particle named LentiFlash. This particle is based on a new chimeric bacteriophage-based lentiviral platform a...
We look forward to sharing with you the results of our new non-integrative MS2-based lentiviral particles for RNA delivery during the upcoming CRISPR congress Europe in Berlin.
We are pleased to announce our 0,9M€ fundraising. Vectalys has raised funds for its development. See our press release here (In french).